证券日报网讯 7月30日晚间，百诚医药发布公告称，公司于2024年12月6日召开第三届董事会第二十五 次会议和第三届监事会第二十一次会议，审议通过了《关于使用部分闲置募集资金暂时补充流动资金的 议案》，同意公司在不影响募集资金项目建设的情况下，使用不超过人民币50，000万元的闲置募集资 金暂时补充流动资金，使用期限为自董事会审议通过之日起不超过12个月。2025年7月30日，公司已将 上述用于暂时补充流动资金的人民币50，000万元闲置募集资金提前归还至募集资金专用账户，本次用 于暂时补充流动资金的募集资金已全部归还完毕，使用期限未超过12个月。 （编辑 任世碧） ...

关于提前归还暂时补充流动资金的闲置募集资金的公告 证券代码：301096 证券简称：百诚医药 公告编号：2025-032 杭州百诚医药科技股份有限公司 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，公告不 存在虚假记载、误导性陈述或重大遗漏。 杭州百诚医药科技股份有限公司（以下简称"公司"）于2024年12月6日召 开第三届董事会第二十五次会议和第三届监事会第二十一次会议，审议通过了 《关于使用部分闲置募集资金暂时补充流动资金的议案》，同意公司在不影响募 集资金项目建设的情况下，使用不超过人民币50,000万元的闲置募集资金暂时补 充流动资金，使用期限为自董事会审议通过之日起不超过12个月，即到期日为 2025 年 12 月 5 日 ， 具 体 内 容 详 见 公 司 于 2024 年 12 月 6 日 在 巨 潮 资 讯 网 （www.cninfo.com.cn）发布的《关于使用部分闲置募集资金暂时补充流动资金 的公告》（公告编号：2024-044）。 2025年7月30日，公司已将上述用于暂时补充流动资金的人民币50,000万元 闲置募集资金提前归还至募集资金专用账户，本次用于暂时补充流动资金 ...

Core Insights - The report maintains a positive outlook on small molecule drug conjugates (SMDCs) and related companies, highlighting their potential in cancer treatment due to their ability to enhance efficacy while reducing toxicity [1][5][17] - The report emphasizes the clinical advantages of SMDCs, including better tumor penetration, reduced toxicity to normal cells, and easier control over synthesis and costs compared to antibody-drug conjugates (ADCs) [5][11][12] - The report identifies domestic biopharmaceutical companies, particularly Affinivax, as leaders in the SMDC space, showcasing significant advancements in innovative cancer drug development [5][12][17] Industry Overview - The pharmaceutical and biotechnology sector has shown a relative price-to-earnings (P/E) ratio of 51.14 as of July 25, 2025, which is significantly higher than its historical low of 24.38, indicating a premium valuation compared to the broader market [19] - The report notes that the healthcare sector's valuation is 279% higher than the Shanghai Composite Index, reflecting strong investor interest and confidence in the industry [19] - Recent market performance indicates a 1.90% increase in the pharmaceutical and biotechnology sector from July 21 to July 25, 2025, ranking it 16th among 27 sub-industries [26][29] Company Focus - The report suggests monitoring companies involved in the SMDC space, including Affinivax, and those collaborating with them, such as Innovent Biologics and others, which are expected to benefit from the growing interest in innovative cancer therapies [5][17][18] - Specific companies highlighted for their innovative drug development capabilities include Innovent Biologics, Shunyi Pharmaceutical, and others, which are positioned to capitalize on the advancements in SMDC technology [5][18]

Core Viewpoint - The Chinese innovative drug industry is experiencing significant growth in the first half of 2025, driven by policy benefits and international breakthroughs, with leading companies achieving explosive growth due to technological barriers and commercialization capabilities [1]. Company Performance Summaries - **Shuanglu Pharmaceutical**: Expected net profit for H1 2025 is between 100 million and 135 million RMB, a year-on-year increase of 237.95% to 356.24% from 29.59 million RMB in the same period last year, primarily benefiting from financial asset returns and breakthroughs in innovative drug pipelines [3][4]. - **Sino Biopharmaceutical**: Anticipated net profit ranges from 77.03 million to 94.14 million RMB, reflecting a year-on-year increase of 253.54% to 332.10%, driven by strong performance in peptide raw material exports [5][7]. - **Microchip Biotech**: Expected net profit of approximately 30.06 million RMB, representing a 173% increase, attributed to the inclusion of its core product (Sida Benamine) in medical insurance and optimized sales strategies [8][10]. - **Buchang Pharmaceutical**: Projected net profit between 488 million and 708 million RMB, a year-on-year increase of 110.88% to 205.94%, due to increased sales scale and reduced production costs [11][13]. - **Ganli Pharmaceutical**: Expected net profit of 600 million to 640 million RMB, a year-on-year increase of 100.73% to 114.12%, driven by significant revenue growth and refined expense management [15][16]. - **Shanghai Pharmaceuticals**: Anticipated net profit of 4.45 billion RMB, an increase of approximately 52% from the previous year, following the acquisition of a 10% stake in Shanghai Hengrui Medicine [17][18]. - **Liaoning Chengda**: Expected net profit between 689 million and 735 million RMB, a year-on-year increase of 50% to 60%, supported by a dual-driven strategy of healthcare and financial investment [19][21]. - **WuXi AppTec**: Projected net profit of approximately 6.3 billion RMB, a year-on-year increase of about 44.43%, driven by optimized CRDMO business models and significant non-operating gains from stock sales [23][25]. - **Notai Biopharmaceutical**: Expected net profit between 300 million and 330 million RMB, a year-on-year increase of 32.06% to 45.27%, attributed to sales growth in peptide raw materials [27][29]. - **I-Wu Biotech**: Anticipated net profit between 170 million and 180 million RMB, reflecting a year-on-year increase of 13.92% to 23.97%, focusing on allergy disease treatment products [30][31]. Industry Trends - The performance divergence in the innovative drug industry in 2025 indicates a shift from "scale competition" to "technological competition," with companies possessing genuine innovation capabilities and international layouts expected to lead, while those relying on capital operations or policy arbitrage face growth challenges [32].

Core Viewpoint - Baicheng Pharmaceutical (301096.SZ) has faced significant financial challenges, reporting a projected net profit of 0 to 6 million yuan for the first half of 2025, a decline of 95.53% to 100% compared to the previous year, with a non-recurring net loss expected between 9 million to 15 million yuan, a drop of 107.31% to 112.18% [1][3] Financial Performance - In 2023, Baicheng Pharmaceutical achieved a revenue of 1.017 billion yuan, a year-on-year increase of 67.51%, and a net profit of 272 million yuan, up 40.07% [3] - The company revised its 2024 performance, reporting a revenue of 802 million yuan, a decrease of 21.18%, and a net loss of approximately 52.74 million yuan, a decline of 119.39% [5] - For 2024, the company projected a net profit of 45 million to 65 million yuan, a decrease of 83.45% to 76.10%, and a non-recurring net profit of 26.1 million to 39.1 million yuan, down 89.91% to 84.89% [4] Research and Development - Baicheng Pharmaceutical's R&D expenses increased from 166 million yuan in 2022 to 318 million yuan in 2024, reflecting a growth of 104.68%, 45.13%, and 32.06% respectively [6] - The company reported a decrease in R&D personnel by 0.16% from 1249 to 1247 individuals by the end of 2024, with a slight reduction in the number of employees holding bachelor's and master's degrees [9][10] Market Activity - Since October 2022, Baicheng Pharmaceutical's stock price has remained below its initial offering price, indicating a prolonged period of underperformance [2][12] - The controlling shareholder, Lou Jinfang, announced plans to increase her stake in the company by investing between 50 million to 100 million yuan, which has led to a slight increase in stock price following the announcement [2][13]

Group 1 - Tiande Yu achieved a net profit of 1.52 billion yuan in the first half of 2025, a year-on-year increase of 50.89% [1] - Tiande Yu's operating income for the same period was 12.08 billion yuan, reflecting a growth of 43.35% year-on-year [1] - Fule New Materials plans to reduce its shareholding by up to 1.33%, amounting to 376.25 million shares, due to personal funding needs [1] - Jindi Co. signed an industrial project investment contract with a total investment of no less than 1.5 billion yuan [1] Group 2 - Tuo Xin Pharmaceutical intends to invest 10 million yuan in Jiangsu Jinsan Biotechnology, acquiring a 1.75% stake [1] - Pinming Technology expects a net profit of 28 million to 34 million yuan for the first half of 2025, a year-on-year increase of 231.79% to 302.89% [4] - Shuanglin Co. anticipates a net profit of 251 million to 310 million yuan, representing a growth of 1% to 25% year-on-year [7] Group 3 - Kangxino received approval for clinical trials of its trivalent poliovirus vaccine [8] - Bailian Co. signed a land storage compensation contract worth approximately 2 billion yuan [9] - Wukuang Development plans to issue short-term financing bonds and medium-term notes totaling up to 2 billion yuan each [10] Group 4 - Hengxin Life intends to invest 10 million yuan in a targeted equity investment [12] - Hengyin Technology expects a net profit of 13.5 million to 16.2 million yuan, marking a turnaround from losses [14] - *ST Jinglun anticipates a net loss of 19 million to 22 million yuan for the first half of 2025 [15] Group 5 - Baiyun Electric won a bid for a State Grid project worth 164 million yuan [16] - Zhejiang Energy completed a power generation of 788.48 billion kWh in the first half of 2025, a year-on-year increase of 4.48% [17] - Sheneng Co. reported a power generation of 259.51 billion kWh, a decrease of 1.7% year-on-year [19] Group 6 - Hengerd signed a strategic cooperation framework agreement with Tiangong International [21] - Baotai's application for the listing of Golimumab injection has been accepted by the FDA [23] - Yishitong received a government subsidy of 2 million yuan [24] Group 7 - Jinggong Steel signed a contract worth approximately 550 million yuan for the Jeddah Stadium project in Saudi Arabia [26] - Zhongwang Software received a government subsidy of 28 million yuan [27] - Rongxin Culture used idle funds of 100 million yuan to purchase financial products [29] Group 8 - Lingxiao Pump Industry invested 80 million yuan in financial products [31] - China Pacific Insurance reported a total original insurance premium income of 282 billion yuan from its subsidiaries [32] - Kema Technology expects a net profit of 165 million to 175 million yuan, a year-on-year increase of 18.59% to 25.77% [32] Group 9 - Qujiang Cultural Tourism anticipates a net loss of approximately 13 million to 16.9 million yuan [32] - Daoshi Technology expects a net profit of 220 million to 238 million yuan, a year-on-year increase of 98.77% to 115.03% [32] - Baicheng Medicine forecasts a net profit decline of 95.53% to 100% [33] Group 10 - Bertley plans to invest 198 million yuan to establish a partnership for investments in emerging fields [34] - China Merchants Highway announced the resignation of its chairman due to reaching retirement age [35] - Overseas Chinese Town A reported a 29% decrease in contract sales amount in June [36]

Key Points - Zhongsheng Gaoke is planning a change in company control, with a potential transfer of 22.35% of shares at a valuation of 2.5 billion yuan, leading to a stock suspension starting July 16, 2025 [3][4] - Yanshan Technology's subsidiary is participating in a partnership to invest 41.64 million yuan in a fund that will ultimately invest in Bytedance Ltd [5] - Sanyuan Bio received an initial ruling of a 450.64% anti-dumping duty from the US Department of Commerce on erythritol, prompting a shift in sales strategy towards domestic markets [6] - Chutianlong is exploring digital currency projects but faces risks related to new technology development and commercial application [7] - Bertley is establishing a partnership to invest in humanoid robots and other emerging sectors, committing 198 million yuan [8] - China Merchants Highway's chairman resigned due to reaching retirement age [9] - Tibet Summit's controlling shareholder is under investigation for information disclosure violations, but it will not affect the company's operations [10][11] - ST Weir plans to acquire 51% of Zijiang New Materials for 546 million yuan, entering the lithium battery materials sector [12] - ST Yazhen's stock will be suspended for three days due to abnormal trading fluctuations [13] - Dahua Technology's subsidiary is shifting its listing to the Hong Kong Stock Exchange [14] Performance Forecasts - Zhongji Xuchuang expects a net profit increase of 52.64% to 86.57% for the first half of 2025, driven by strong demand for high-end optical modules [15] - Juchip Technology anticipates a 122.28% increase in net profit for the same period, benefiting from successful AI audio chip promotions [16] - Sitwei forecasts a net profit growth of 140% to 180%, with significant revenue increases from smartphone collaborations [17] - Tianyu Co. expects a net profit increase of 144.29% to 238.25%, aided by improved product structure and market strategies [18] - Jinli Yongci predicts a net profit growth of 151% to 180%, focusing on renewable energy and related sectors [19] - Blue Ocean Huaten expects a net profit increase of 152.76% to 190.68%, driven by growth in the new energy heavy truck market [20] - Maiqu'er anticipates a turnaround with a net profit of 1.4 million to 2 million yuan, compared to a loss in the previous year [21] - China Galaxy expects a net profit increase of 45% to 55%, with growth across various business segments [23] - Baicheng Pharmaceutical forecasts a significant decline in net profit, down 95.53% to 100% [24] Major Contracts - Jincheng signed a contract worth approximately 52.98 million USD for underground mining operations in the Democratic Republic of Congo [25] - ST Yundong entered a strategic cooperation agreement for drone development and investment with two companies [26] - Changgao Electric New's subsidiary won contracts totaling 445 million yuan from the State Grid [27] Shareholding Changes - Angli Education plans to reduce its repurchased shares by up to 573.1 million shares [28][29] - Lingzhi Software's shareholders plan to collectively reduce their holdings by up to 2.11% [30] - Founder Technology's major shareholder intends to reduce its stake by up to 2.27% [31] - Zhongfu Shenying's shareholder plans to reduce its stake by up to 1% [32] - Hangzhou Bank's shareholder intends to reduce its stake by up to 0.7% [33] - Haoyun Technology's chairman plans to reduce his stake by up to 400,000 shares [34] Financing Activities - Yuanwang Valley plans to raise up to 300 million yuan through a private placement for RFID production line projects and working capital [35]

百诚医药（301096）公告，预计2025年1月1日至2025年6月30日，归属于上市公司股东的净利润为0万 元–600万元，同比下降95.53%-100.00%。上年同期净利润为1.34亿元。扣除非经常性损益后的净利润为 亏损900万元–1500万元，上年同期为1.23亿元。公司预计非经常性损益对净利润的影响金额约为1500万 元，主要为政府补助收入。 ...

[Hangzhou Baicheng Pharmaceutical Technology Co., Ltd. 2025 Semi-Annual Performance Forecast](index=1&type=section&id=Hangzhou%20Baicheng%20Pharmaceutical%20Technology%20Co.%2C%20Ltd.%202025%20Semi-Annual%20Performance%20Forecast) [Core Performance Forecast Data](index=1&type=section&id=I.%20Current%20Period%20Performance%20Forecast) The company anticipates a substantial year-over-year decline in its 2025 first-half performance, with net profit attributable to shareholders projected to be between 0 and 6 million yuan Performance Forecast Summary | Item | Current Reporting Period (Jan 1 - Jun 30, 2025) | Prior Period | | :--- | :--- | :--- | | **Net Profit Attributable to Shareholders of Listed Company** | Profit: 0 Million Yuan – 6 Million Yuan | Profit: 134.2105 Million Yuan | | | Year-over-Year Decrease: 95.53% - 100.00% | | | **Net Profit After Non-Recurring Items** | Loss: 9 Million Yuan – 15 Million Yuan | Profit: 123.1989 Million Yuan | | | Year-over-Year Decrease: 107.31% - 112.18% | | [Communication with Accounting Firm](index=1&type=section&id=II.%20Communication%20with%20Accounting%20Firm) The company has pre-communicated with its accounting firm regarding the performance forecast, confirming no major discrepancies, though the forecast remains unaudited - The financial data in this performance forecast is unaudited by the accounting firm, but the company has pre-communicated with the accounting firm on related matters, and there are no significant discrepancies between the parties[5](index=5&type=chunk) [Analysis of Performance Changes](index=2&type=section&id=III.%20Explanation%20of%20Performance%20Changes) The company attributes performance changes to increased Q2 revenue from R&D commercialization and strict cost control, alongside significant government subsidies - In the second quarter of 2025, the company intensified the commercialization of its independent R&D achievements, leading to a sequential increase in revenue and achieving a turnaround from loss to profit in the first half compared to 2024 through strict cost and expense control[6](index=6&type=chunk) - During the reporting period, the estimated impact of non-recurring gains and losses on net profit is approximately **15 million yuan**, primarily from government subsidies recognized in current profit or loss[6](index=6&type=chunk) [Risk Warning and Other Explanations](index=2&type=section&id=IV.%20Other%20Related%20Explanations) The company states this performance forecast is preliminary, with final data in the 2025 semi-annual report, advising investors to exercise caution - This performance forecast represents preliminary data from the company's finance department; the final financial data will be subject to the company's 2025 semi-annual report, and investors are advised to be aware of investment risks[7](index=7&type=chunk)

Group 1 - The CRO sector experienced a slight increase of 0.66% with a total capital inflow of 84.32 million [1] - A total of 27 stocks within the sector saw gains, while 11 stocks experienced declines [1] - The top declining stocks included Yaokang Bio (-3.64%), Zhaoyan New Drug (-2.68%), and Meidi West (-2.04%) [1] Group 2 - Notable stocks with significant capital inflow included Baicheng Pharmaceutical with a price of 48.06 and a rise of 6.05% [1] - Other stocks with positive performance included Heyuan Bio (+4.39%) and Jinkai Biotechnology (+2.76%) [1] - The stock with the highest capital outflow was Yao Stone Technology, which saw a decrease of 8.88% [1]